Medicare Keeps Limits on Coverage of Biogen Alzheimer’s Drug (2)

The U.S. Medicare program finalized a plan to restrict coverage for Biogen Inc.’s Alzheimer’s therapy to patients in certain clinical trials, while offering a road map to cover drugs that show clinical benefit in the treatment of the disease.

The decision announced Thursday will effectively prevent most Alzheimer’s patients from receiving Biogen’s Aduhelm. Yet Medicare officials said that the policy would provide broader coverage to future drugs that show a clear benefit in large trials and get full approval from the Food and Drug Administration.

It’s a blow to Biogen, which has been campaigning for the Centers for Medicare ...